DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism

Information source: Vilnius University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Opiate Addiction

Intervention: Naltrexone (Drug); Clonidine (Drug); Lorazepam (Drug)

Phase: N/A

Status: Completed

Sponsored by: Vilnius University

Official(s) and/or principal investigator(s):
ROBERTAS BADARAS, MD, Principal Investigator, Affiliation: Vilnius University Clinic of Anaesthesiology and Intensive Care
JUOZAS IVASKEVICIUS, PROFESSOR, Study Director, Affiliation: Vilnius University Clinic of Anaesthesiology and Intensive Care

Summary

The aim of this study is to investigate which method of naltrexone induction during rapid opioid detoxification causes stronger stress response and has a higher influence on opioid abstinence caused by opioid induction.

Clinical Details

Official title: The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism With Naltrexone and Sedation

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Cortisol levels

Adrenocorticotropic hormone (ACTH) levels

Secondary outcome:

Stress response levels according to heart rate

Stress response levels according to respiratory rate

Stress response levels according to blood pressure

Changes of potassium concentration due to stress response

Changes of sodium concentration due to stress response

Changes of chloride concentration due to stress response

Changes of magnesium concentration due to stress response

Changes of glucose concentration due to stress response

Subjective Opiate Withdrawal Scale (SOWS)

Objective Opiate Withdrawal Scale (OOWS)

Detailed description: Study enrolls opiate addicted patients who are motivated for a long term treatment and full opiate abstinence. Patient is offered to take part in a study. Information is provided regarding protocol, aim and course of study. Patients who are eligible and consent for study commit to follow the pre-study recommendations. Study consists of:

Primary assessment - information about study. Assessment of patient according to predefined

criteria. Consent form. Allocation of the treatment date.

Stabilization - Buprenorphine. Assessment according to SOWS and OWS. Total amount of

buprenorphine is recorded.

Repeated evaluation - patient after successful stabilization course undergoes urine test for

psychotropic substances, blood alcohol level is recorded. If any test is positive patient is not enrolled to study.

Correction of opioid withdrawal symptoms - all of the patients receive medicines for opioid

detoxification, infusion therapy in predefined doses.

Antagonist induction - patients receive opioid antagonist (incremental or standard dose).

Withdrawal symptoms are assessed and correction with lorazepam is given if needed.

Data collection - data is recorded (demographic, epidemiological, vital signs, opioid

withdrawal symptoms, levels of hormones, metabolites, electrolytes).

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Opiate addiction

- Use of short-acting opiate (morphine or heroine)

- Age > 18 years

- Length of opiate addiction > 1 year

- Patient can make a decision for detoxification and has a capacity to consent for

procedure

- Written consent for procedure

Exclusion Criteria:

- Polyvalent addiction

- Pregnancy or breast feeding

- Cardiovascular pathology

- Acute or chronic kidney disease

- Decompensated liver pathology (jaundice, ascites, hepatic encephalopathy)

- Infective complications of opiate addiction (pneumonia, phlegmon, abscess,

thombophlebitis, sepsis)

- Malnutrition (Nutritional risk screening 2002 score ≥3)

- Diabetes mellitus

- Previous history of psychosis

- Glasgow coma scale < 15

- Abdominal surgical intervention during last 30 days

- Cumulative buprenorphine dose for stabilization < 8 mg

- Positive test for psychoactive substances during treatment

- Refusal to participate in study at any point of it

Locations and Contacts

Republic Vilnius University Hospital, Vilnius LT-04130, Lithuania
Additional Information

Intermediate data

Starting date: May 2014
Last updated: February 11, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017